HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Noda, A. Articles by Nishimura, S. Search for Related Content PubMed PubMed Citation Articles by Noda, A. Articles by Nishimura, S.

Measurement of Brain Concentration of FK960 for Development of a Novel Antidementia Drug: A PET Study in Conscious Rhesus Monkeys

¹ The Medical and Pharmacological Research Center Foundation, Hakui, Japan
² Department of Biotracer Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
³ Advanced Technology Platform Research Laboratory, Fujisawa Pharmaceutical Company, Ltd., Tsukuba, Japan
⁴ Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Company, Ltd., Osaka, Japan

View larger version (7K): [in a new window]   FIGURE 1. Chemical structure of FK960 (N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate). Asterisk denotes position of 18F labeling.

View larger version (123K): [in a new window]   FIGURE 2. Typical PET images obtained from 30 to 90 min after administration of 18F-FK960 preparation. Presented images are 3.6-mm transverse slices, and slice 6 corresponds to orbitomeatal plane.

View larger version (21K): [in a new window]   FIGURE 3. Time–concentration curves for plasma and brain after peroral administration of FK960 (0.1 mg/kg) containing 18F-FK960 (366 ± 14 MBq). Data are presented as mean + SE, averaged over all subjects (n = 3), at each point.